EDGC and Targetnos team up on digital PCR prenatal test

By AI, Created 4:53 PM UTC, May 18, 2026, /AGP/ – EDGC and Targetnos Biotechnology are working together to validate and commercialize a digital PCR-based noninvasive prenatal testing platform for global markets. The deal could broaden access to lower-cost prenatal screening for common fetal aneuploidies, including Trisomy 21, 18 and 13.

Why it matters: - Digital PCR-based NIPT could sit between low-cost serum screening and higher-priced next-generation sequencing tests. - The companies say that position could widen access to more accurate prenatal screening while keeping costs and scalability in reach for more clinics and patients. - The collaboration targets a large global prenatal diagnostics market where affordability and clinical performance remain major barriers.

What happened: - Eone Diagnomics Genome Center, or EDGC, announced a strategic collaboration with Targetnos Biotechnology Co., Ltd. on May 13, 2026. - The partnership aims to pursue global validation and commercialization of a digital PCR-based noninvasive prenatal testing solution. - EDGC is based in South Korea. - Targetnos is headquartered in Hangzhou, China.

The details: - Targetnos has developed a digital PCR-based NIPT kit that can detect fetal aneuploidies from maternal blood, including Trisomy 21, Trisomy 18 and Trisomy 13. - The kit is described as the only digital PCR-based NIPT solution of its kind in China and one of only a few globally. - The assay has been clinically validated across hundreds of patient samples. - The companies say the test has shown high accuracy, reproducibility and cost-effectiveness. - EDGC brings global NIPT operations and clinical genomics experience to the partnership. - EDGC was among the first companies to develop and commercialize NGS-based NIPT testing in Korea under the NICE brand. - EDGC now provides genomic testing services in more than 30 countries. - Targetnos focuses on molecular diagnostics products built on digital PCR platforms.

Between the lines: - The partnership is also a positioning move in prenatal diagnostics, where digital PCR could offer a middle ground for providers that want better performance than serum screening without the cost structure of NGS-based testing. - The companies are signaling a push beyond one product, with the collaboration expected to extend to other joint projects. - The emphasis on clinical studies and technology optimization suggests the commercial rollout still depends on additional validation work.

What’s next: - EDGC and Targetnos plan additional clinical studies to strengthen the evidence base for the test. - The companies also plan technology optimization before broader market expansion. - Future work will focus on global prenatal diagnostics markets. - The collaboration may expand into other projects that combine the two companies’ strengths.

The bottom line: - EDGC and Targetnos are betting that digital PCR can make advanced prenatal screening more accessible without sacrificing clinical performance.